Hospital Santa Caterina Ias
- Address
- Calle Del Doctor Castany S/N, 17190 Salt, Spain
Hospital Santa Caterina IAS - Multiple Sclerosis Research Center
Hospital Santa Caterina IAS is a specialized clinical research center with a distinguished focus on multiple sclerosis (MS) therapeutic development. The center demonstrates comprehensive expertise in evaluating innovative disease-modifying therapies across the full spectrum of MS subtypes, including relapsing-remitting, relapsing, and primary progressive forms of the disease.
- Advanced B-cell targeted therapies including ofatumumab and ocrelizumab studies for relapsing multiple sclerosis
- Bruton's tyrosine kinase (BTK) inhibitors for primary progressive MS and novel oral agents like remibrutinib
- Long-term safety and efficacy extension studies tracking disease-modifying treatments
- Women's health research focused on pregnancy-related conditions
The center's research portfolio emphasizes both early-line treatment strategies for newly diagnosed patients and long-term rollover studies that assess sustained safety and efficacy of immunomodulatory therapies. With extensive experience in pharmacokinetic and pharmacodynamic studies, biosimilar evaluations, and comparative effectiveness trials, Hospital Santa Caterina IAS plays a crucial role in advancing the understanding of MS disease progression and treatment optimization. The center's participation in international multicenter trials demonstrates its commitment to contributing to global MS research initiatives.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 62 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 62 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Zenas Biopharma (USA) LLC2active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG4trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Santa Caterina Ias
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multi-Center, Double-Blind, Placebo-Controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, A Monoacylglycerol Lipase Inhibitor, as Add-On Therapy to Ocrelizumab, in Participants with Progressive Forms of Multiple Sclerosis | F. Hoffmann-La Roche AG | Phase II | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 62 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ocrelizumab | 4 | Unknown | 2022-06-23 | 2026-02-04 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.